INTRODUCTION {#sec1}
============

Viruses are ubiquitous entities co-existing with cellular life forms, present in almost all explored environments (Koonin and Dolja [@bib44]). Viruses that infect bacteria (bacteriophages or phages) are the most abundant biological entities on the planet with population numbers in the order of 10^31^(Suttle [@bib83]; Koonin and Dolja [@bib44]; Guemes *et al*. [@bib28]). The ability of phages to easily manoeuvre between different biomes, operating as vehicles of horizontal gene transfer (HGT), makes them major agents of evolution (Sano *et al*. [@bib73]). Bacteriophages are classified based on their life-cycle into virulent and temperate. Virulent phages rely exclusively on productive infection cycles for propagation, which ultimately kills the host for the release of new viral particles that can engage in another round of infection. Temperate phages have the choice to multiply in their host cells leading to cell lysis or to integrate their phage genome into the bacterial chromosome as a prophage. Prophages are propagated passively by the replication machinery of the bacterial cell (Gandon [@bib25]).

As a response to the constant threat of phage infection, a diverse arsenal of defence mechanisms has evolved in bacterial hosts. Because phages evolve rapidly to counter these immune systems (Drake *et al*. [@bib21]), the hosts need to constantly evolve new means of self-protection, leading to a perennial arms-race between hosts and their phages (Forterre and Prangishvili [@bib23]). The defence systems evolved by bacteria provide both innate and adaptive immunity against phage infection. Innate immunity systems interfere at different levels of the phage\'s infection cycle via receptor masking, superinfection exclusion (Sie), restriction--modification (R-M), bacteriophage exclusion (BREX), toxin--antitoxin (TA) modules, abortive infection (Abi), prokaryotic Argonautes (pAgos), production of anti-phage chemicals and defence island system associated with restriction--modification (DISARM) systems (Chopin, Chopin and Bidnenko [@bib13]; Makarova *et al*. [@bib53]; Makarova, Wolf and Koonin [@bib52]; Samson *et al*. [@bib72]; Goldfarb *et al*. [@bib27]; Kronheim *et al*. [@bib46]), whereas other remain to be characterized (Doron *et al*. [@bib20]). Adaptive and heritable immunity is provided by Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)--CRISPR-associated (Cas) systems (Barrangou *et al*. [@bib1]), which work as a fascinating complementation to the innate defence strategies.

Diverse variants of the CRISPR-Cas defence system are present in most of the sequenced genomes of archaea and half of those of bacteria (Makarova *et al*. [@bib52]). A CRISPR-Cas locus typically consists of a CRISPR array and an operon of CRISPR-associated (*cas*) genes. The CRISPR array is composed of a series of short, partially palindromic and direct repetitive sequences (repeats) interspaced by variable sequences (spacers), originating from phage genomes or other invading mobile genetic elements (MGE), such as (conjugative) plasmids (Bolotin *et al*. [@bib3]; Mojica *et al*. [@bib58]; Pourcel, Salvignol and Vergnaud [@bib68]; Shmakov *et al*. [@bib77]). The *cas* genes encode for the Cas proteins, which are necessary for the generation of new spacers or are involved in the targeting of the MGE, as explained below. Collectively, these two elements of CRISPR-Cas systems mediate sequence-specific immunity against invasive MGEs (Brouns *et al*. [@bib8]; Marraffini and Sontheimer [@bib55]; Hale *et al*. [@bib31]; Garneau *et al*. [@bib26]).

The continuous arms-race between prokaryotic hosts and their cognate MGEs is speculated to be responsible for the rapid evolution of highly diverse CRISPR-Cas systems. The current CRISPR-Cas classification scheme distinguishes two broad classes based on the protein composition of the effector Cas complex. Class 1 systems (types I, III and IV) use multi-subunit Cas protein complexes for the recognition of targeted nucleic acids, while the less common class 2 systems (types II, V and VI) employ a single multi-domain effector protein complex that performs target recognition and cleavage. These classes are further subdivided into a total of six CRISPR types with 25 subtypes (Koonin, Makarova and Zhang [@bib45]).

Despite substantial structural and functional diversity, all CRISPR-Cas systems mediate immunity through three distinct steps: adaptation, expression and interference (Mohanraju *et al*. [@bib57]). During adaptation, short DNA fragments (known as protospacers) are acquired from invading MGEs and subsequently processed and inserted as spacers into the CRISPR locus, typically by the Cas1--Cas2 complex (Jackson *et al*. [@bib37]). Next, during expression, the CRISPR array is transcribed as a long precursor CRISPR RNA (pre-crRNA) and the Cas proteins are expressed. The pre-crRNA is then processed within repeat regions to yield mature CRISPR RNAs (crRNAs) by dedicated Cas proteins and/or host factors (Brouns *et al*. [@bib8]; Hale *et al*. [@bib30]; Haurwitz *et al*. [@bib33]; Deltcheva *et al*. [@bib15]). The crRNAs are packaged with one or more Cas proteins into effector Cas complexes that scrutinise the microbial cell for potential invasion. Finally, during interference, the Cas complexes recognize complementary target sequences of invading MGEs by Watson--Crick base-pairing. Upon binding to a cognate target sequence, the complex either recruits a nuclease or stimulates its intrinsic nuclease activity to neutralize the invader (Brouns *et al*. [@bib8]; Garneau *et al*. [@bib26]; Westra *et al*. [@bib94]). Type I, II and V CRISPR-Cas systems target DNA and rely on a short stretch (2 to 7 nucleotides) of conserved nucleotides adjacent to the protospacer, known as the protospacer-adjacent motif (PAM), for spacer selection during adaptation and target identification during interference (Mojica *et al*. [@bib58]; Marraffini and Sontheimer [@bib55]). The PAM allows for self/nonself discrimination, as its absence in the CRISPR array prevents autoimmunity and self-cleavage.

In response to the microbial antiviral defence mechanisms, phages have evolved numerous mechanisms to overcome prokaryotic immunity. Phage evasion from prokaryotic CRISPR-Cas systems was first found to rely on mutational drifts, predominantly occurring in regions that require perfect complementarity between the crRNA and the protospacer (so-called seed region) for interference, or in the PAM sequences (Deveau *et al*. [@bib16]; Sun *et al*. [@bib82]; Bondy-Denomy *et al*. [@bib5]). Depending on the location of the mismatch (between the crRNA and the protospacer), a single mutation can be sufficient to abolish CRISPR-Cas immunity (Deveau *et al*. [@bib16]; Semenova *et al*. [@bib75]). Deletion of the protospacer sequence and/or the PAM have also been shown to provide an effective way for phages to escape CRISPR-Cas targeting, despite the potential of imposing a fitness cost (Deveau *et al*. [@bib16]). Similar to the evasion strategy from R-M systems, phages can also modify their bases with hydroxymethylcytosine (HMC) and its bulkier glycosylated form to reduce target binding affinity and thereby protect from CRISPR-mediated targeting by both type I and type II systems (Bryson *et al*. [@bib10]; Vlot *et al*. [@bib88]), whereas other modifications do not disturb Cas9 recognition (Yaung, Esvelt and Church [@bib97]). Finally, some phages encode their own CRISPR locus that targets host antiviral genomic regions, such as chromosomal (defence) islands (Seed *et al*. [@bib74]).

The first examples of phage-encoded anti-CRISPR (Acr) proteins were found in class 1 type I-F and I-E systems of *Pseudomonas aeruginosa* (Bondy-Denomy *et al*. [@bib4]; Pawluk *et al*. [@bib63]). Acr proteins have distinct sequences (Tables [1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}), structures (Maxwell *et al*. [@bib56]; Wang *et al*. [@bib90]; Harrington *et al*. [@bib32]) and mechanisms (Bondy-Denomy *et al*. [@bib5]) and they provide phages with a direct and specific means to inhibit targeting by the CRISPR-Cas system. To date, 45 unique families of Acr proteins have been discovered, and categorized into class 1 (Table [1](#tbl1){ref-type="table"}) and class 2 (Table [2](#tbl2){ref-type="table"}) CRISPR-Cas inhibitors. These highly diverse and small (typically 50--330 amino acids) proteins do not share much sequence or protein domain similarity to each other or to any protein of known function (Marino *et al*. [@bib54]).

![Different discovery and testing methods of Acrs. **(A)** Guilt-by-association discovery method (Pawluk *et al*. [@bib65]). This discovery method is based on the strong co-occurrence and clustering of *acr* and *aca* genes through proximity and homology searches. In this example, homology searches using the *acr1* gene yields its homologue *acr1.1*. Inspection of genes in close proximity yielded *acaY.1*, which in turn can be used for further iterative rounds of *acr* and/or *aca* gene discovery. Both *acr* and *aca* genes typically appear in clusters leading to the discovery of new *acr* and *aca* genes. **(B)** The self-targeting discovery method (Rauch *et al*. [@bib69]). The presence of a self-targeting spacer (in green) within the CRISPR array hints at the presence of a (set of) *acr* gene(s) (in purple) somewhere within the host\'s genome, often within prophage regions. **(C)** Low- and high-throughput functional assays to identify phage-encoded Acrs. In a low-throughput assay, individual phages are used to screen for anti-CRISPR activity in hosts with a CRISPR-Cas system targeting the phage (left) using (for example) plaque assays. High-throughput screening can be performed by transforming phage ORF libraries that are placed on a plasmid containing a protospacer. Successful transformants can be screened further to pinpoint the gene with the Acr activity within the collection of ORFs.](fnz098fig1){#fig1}

###### 

Class 1 anti-CRISPR protein families.

  Family      Size (aa)   Origin (characterized homolog)                       Method of discovery                                  Accession number   CRISPR-Cas type inhibited \[organism\]   Mode-of-action                                                                                                                                                          Structure                                                                                                            PDB code                 References
  ----------- ----------- ---------------------------------------------------- ---------------------------------------------------- ------------------ ---------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- ------------------------ ---------------------------------------------------------------------------------------------------------------------
  AcrIC1      190         *Moraxella bovoculi* prophage                        Self-targeting, Guilt-by-association \[*acrIF11*\]   AKG19229.1         I-C \[Mbo\]                              ---                                                                                                                                                                     ---                                                                                                                  ---                      (Marino *et al*. [@bib54])
  AcrID1      98          *Sulfolobus islandicus* rudivirus 3                  Functional assays                                    YP_009272954.1     I-D \[Sis\]                              Binds as a dimer to the Cas10d, mimicking DNA (blocks DNA binding)                                                                                                      Compact dimeric αβ-sandwich; each monomer 5-stranded antiparallel β-sheet + 2 α-helices at one side of the β-sheet   6EXP                     (He *et al*. [@bib34])
  AcrIE1      100         *Pseudomonas aeruginosa* phage JBD5                  Functional assays                                    YP_007392738.1     I-E \[Pae\]                              Binds as a dimer to the Cas3 (blocks DNA cleavage)                                                                                                                      Elongated dimeric structure; each monomer 1 antiparallel β-sheet + 3 α-helices                                       6ARZ, 6AS4               (Pawluk *et al*. [@bib63]), (Pawluk *et al*. [@bib64])
  AcrIE2      84          *P. aeruginosa* phage JBD88a                         Functional assays                                    YP_007392439.1     I-E \[Pae\]                              ---                                                                                                                                                                     ---                                                                                                                  ---                      (Pawluk *et al*. [@bib63])
  AcrIE3      68          *P. aeruginosa* phage DMS3                           Functional assays                                    YP_950454.1        I-E \[Pae\]                              Probably binds to the Cascade (blocks DNA binding)                                                                                                                      ---                                                                                                                  ---                      (Pawluk *et al*. [@bib63])
  AcrIE4      52          *P. aeruginosa* phage D3112                          Functional assays                                    NP_938238.1        I-E \[Pae\]                              ---                                                                                                                                                                     ---                                                                                                                  ---                      (Pawluk *et al*. [@bib63])
  AcrIE5      65          *Pseudomonas otitidis* mobile genetic element        Guilt-by-association \[*aca1*\]                      WP_074973300.1     I-E \[Pae\]                              ---                                                                                                                                                                     ---                                                                                                                  ---                      (Marino *et al*. [@bib54])
  AcrIE6      79          *P. aeruginosa* mobile genetic element               Guilt-by-association \[*aca1*\]                      WP_087937214.1     I-E \[Pae\]                              ---                                                                                                                                                                     ---                                                                                                                  ---                      (Marino *et al*. [@bib54])
  AcrIE7      106         *P. aeruginosa* mobile genetic element               Guilt-by-association \[*aca1*\]                      WP_087937215.1     I-E \[Pae\]                              ---                                                                                                                                                                     ---                                                                                                                  ---                      (Marino *et al*., [@bib54])
  AcrIF1      78          *P. aeruginosa* phage JBD30                          Functional assays                                    YP_007392342.1     I-F \[Pae, Pec\]                         2--3 copies interact with the hexameric Cas7f spine of the Cascade (block DNA binding)                                                                                  4-stranded antiparallel β-sheet + 2 α-helices at one side of the β-sheet                                             2LW5, 5UZ9, 6ANV, 6B46   (Bondy-Denomy *et al*. [@bib4]), (Guo *et al*., [@bib29]), (Chowdhury *et al*. [@bib14])
  AcrIF2      90          *P. aeruginosa* phage D3112                          Functional assays                                    NP_938237          I-F \[Pae, Pec\]                         Binds to the Cas5f:Cas8f tail of the Cascade, mimicking DNA (blocks DNA binding)                                                                                        4-stranded antiparallel β-sheet + 2 antiparallel α-helices at either side of the β-sheet                             5UZ9, 6B47               (Bondy-Denomy *et al*. [@bib4]), (Guo *et al*., [@bib29]), (Chowdhury *et al*. [@bib14])
  AcrIF3      139         *P. aeruginosa* phage JBD88a                         Functional assays                                    YP_007392440.1     I-F \[Pae\]                              Binds as a dimer to the Cas3, preventing its recruitment to the Cascade-dsDNA (blocks DNA binding) or spacer acquisition by the Cas1--2/3 complex (blocks adaptation)   Dimeric structure; each monomer 6 α-helices                                                                          5GNF, 5GQH, 5B7I         (Bondy-Denomy *et al*. [@bib4]), (Vorontsova *et al*. [@bib89]), (Wang *et al*. [@bib90]), (Wang *et al*. [@bib91])
  AcrIF4      100         *P. aeruginosa* phage JBD26                          Functional assays                                    WP_016068584.1     I-F \[Pae\]                              Binds to the Cascade (blocks DNA binding)                                                                                                                               ---                                                                                                                  ---                      (Bondy-Denomy *et al*. [@bib4])
  AcrIF5      79          *P. aeruginosa* phage JBD5                           Functional assays                                    YP_007392740.1     I-F \[Pae\]                              ---                                                                                                                                                                     ---                                                                                                                  ---                      (Bondy-Denomy *et al*. [@bib4])
  AcrIF6      100         *P. aeruginosa* prophage                             Guilt-by-association \[*aca1*\]                      WP_043884810       I-F \[Pae, Pec\], I-E \[Pae\]            ---                                                                                                                                                                     ---                                                                                                                  ---                      (Pawluk *et al*.[@bib65])
  AcrIF7      83          *P. aeruginosa* prophage                             Guilt-by-association \[*aca1*\]                      ACD38920.1         I-F \[Pae, Pec\]                         ---                                                                                                                                                                     ---                                                                                                                  ---                      (Pawluk *et al*. [@bib65])
  AcrIF8      92          *Pectobacterium carotovorum* phage ZF40              Guilt-by-association \[*aca2*\]                      AFC22483.1         I-F \[Pae, Pec\]                         ---                                                                                                                                                                     ---                                                                                                                  ---                      (Pawluk *et al*. [@bib65])
  AcrIF9      68          *Vibrio parahaemolyticus* mobile genetic element     Guilt-by-association \[*aca2*\]                      WP_031500045.1     I-F \[Pae, Pec\]                         ---                                                                                                                                                                     ---                                                                                                                  ---                      (Pawluk *et al*. [@bib65])
  AcrIF10     97          *Shewanella xiamenensis* prophage                    Guilt-by-association \[*aca2*\]                      KEK29119           I-F \[Pae, Pec\]                         Binds to the Cas7f:Cas8f tail, mimicking DNA (blocks DNA binding)                                                                                                       4-stranded antiparallel β-sheet + 3 antiparallel α-helices at one side of the β-sheet                                6ANW, 6B48               (Pawluk *et al*. [@bib65]), (Guo *et al*. [@bib29])
  AcrIF11     132         *P. aeruginosa* mobile genetic element               Guilt-by-association \[*aca1*\]                      WP_038819808.1     I-F \[Pae\]                              ---                                                                                                                                                                     ---                                                                                                                  ---                      (Marino *et al*. [@bib54])
  AcrIF12     124         *P. aeruginosa*                                      Guilt-by-association \[*aca4*\]                      ABR13388.1         I-F \[Pae\]                              ---                                                                                                                                                                     ---                                                                                                                  ---                      (Marino *et al*. [@bib54])
  AcrIF13     115         *Moraxella catarrhalis* prophage                     Self-targeting, Guilt-by-association \[*acrIF11*\]   EGE18854.1         I-F \[Mbo\]                              ---                                                                                                                                                                     ---                                                                                                                  ---                      (Marino *et al*. [@bib54])
  AcrIF14     124         *M. catarrhalis* phage Mcat5                         Self-targeting, Guilt-by-association \[*acrIF11*\]   AKI27193.1         I-F \[Mbo\]                              ---                                                                                                                                                                     ---                                                                                                                  ---                      (Marino *et al*. [@bib54])
  AcrIE4-F7   119         *Pseudomonas citronellolis* mobile genetic element   Guilt-by-association \[*aca1*\]                      WP_064584002.1     I-E \[Pae\], I-F \[Pae\]                 ---                                                                                                                                                                     ---                                                                                                                  ---                      (Marino *et al*. [@bib54])

###### 

Class 2 anti-CRISPR protein families.

  Family     Size (aa)   Origin (characterized homolog)                        Method of discovery                                                Accession number   CRISPR-Cas type inhibited \[organism\]                       Mode-of-action                                                                                                                                  Structure                                                                                                                                                                    PDB code                 References
  ---------- ----------- ----------------------------------------------------- ------------------------------------------------------------------ ------------------ ------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------
  AcrIIA1    149         *Listeria monocytogenes* prophage J0161a              Self-targeting                                                     WP_003722518.1     II-A \[Lmo\]                                                 Recognizes nucleic acids (putative transcriptional regulation)                                                                                  Dimeric structure with pseudo 2-fold symmetry; each monomer 5 α-helices + 13~10~ helix at N-terminus and 3 α-helices + 23~10~ helices at C-terminus (all helical 2-domain)   5Y6A                     (Rauch *et al*. [@bib69]), (Ka *et al*. [@bib41])
  AcrIIA2    123         *L. monocytogenes* prophage J0161a                    Self-targeting                                                     WP_003722517.1     II-A \[Lmo, Spy\]                                            Binds to the PAM-interacting, the WED, the HNH, and the REC2 domains (blocks DNA recognition, binding/unwinding, and cleavage, respectively)    Bent 4-stranded antiparallel β-sheet + 2 α-helices at either side of the β-sheet                                                                                             6MCB, 6MCC, 6IFO         (Rauch *et al*. [@bib69]), (Jiang *et al*. [@bib38]), (Liu *et al*. [@bib51])
  AcrIIA3    125         *L. monocytogenes* prophage SLCC2482                  Self-targeting, Guilt-by-association \[*acrIIA1*\]                 WP_014930691.1     II-A \[Lmo\]                                                 ---                                                                                                                                             ---                                                                                                                                                                          ---                      (Rauch *et al*. [@bib69])
  AcrIIA4    87          *L. monocytogenes* prophage J0161b                    Self-targeting, Guilt-by-association \[*acrIIA1*\]                 WP_003723290.1     II-A \[Lmo, Spy\]                                            Binds to the PAM-interacting, the Topo-homology, and the RuvC domains (blocks DNA recognition, binding/unwinding, and cleavage, respectively)   3-stranded antiparallel β-sheet + 3 α-helices at one side of the β-sheet + 13~10~ helix                                                                                      5XN4, 5XBL, 5VW1, 5VZL   (Rauch *et al*. [@bib69]), (Kim *et al*. [@bib1_828_1558689730776]), (Dong *et al*. [@bib18]), (Yang and Patel, [@bib96]), (Shin *et al*. [@bib76])
  AcrIIA5    140         *Streptococcus thermophilus* (virulent) phage D4276   Functional assays                                                  ASD50988.1         II-A \[Sth1, Sth3, Spy\]                                     ---                                                                                                                                             ---                                                                                                                                                                          ---                      (Hynes *et al*. [@bib36])
  AcrIIA6    183         *S. thermophilus* (virulent) phage D1811              Functional assays, Guilt-by-association \[*acrIIA5*\]              MH000604           II-A \[Sth1\]                                                ---                                                                                                                                             Dimeric structure; each monomer 4-stranded antiparallel β-sheet + 8 α-helices                                                                                                6EYX,                    
  6EYY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  (Hynes *et al*. [@bib36])
  AcrIIA7    103         Human gut metagenomic libraries                       Synthetic genetic circuit for screening of metagenomic libraries   LR030272           II-A \[Spy\]                                                 ---                                                                                                                                             ---                                                                                                                                                                          ---                      (Uribe *et al*. [@bib85])
  AcrIIA8    105         Human gut metagenomic libraries                       Synthetic genetic circuit for screening of metagenomic libraries   LR030270           II-A \[Spy\]                                                 ---                                                                                                                                             ---                                                                                                                                                                          ---                      (Uribe *et al*. [@bib85])
  AcrIIA9    141         Human gut metagenomic libraries                       Synthetic genetic circuit for screening of metagenomic libraries   LR030269           II-A \[Spy\]                                                 ---                                                                                                                                             ---                                                                                                                                                                          ---                      (Uribe *et al*. [@bib85])
  AcrIIA10   109         Soil metagenomic libraries                            Synthetic genetic circuit for screening of metagenomic libraries   LR030271           II-A \[Spy\]                                                 ---                                                                                                                                             ---                                                                                                                                                                          ---                      (Uribe *et al*., [@bib85])
  AcrIIC1    86          *Neisseria meningitidis* mobile genetic element       Guilt-by-association \[*aca2*\]                                    WP_049360089.1     II-C \[Nme,Cje, Geo, Hpa, Smu\]                              Binds to the HNH active site (allows DNA binding, blocks DNA cleavage)                                                                          5-stranded β-bundle interspaced by 2 α-helices                                                                                                                               5VGB                     (Pawluk *et al*. [@bib66]), (Harrington *et al*. [@bib32]), (Lee *et al*. [@bib49]), (Zhu *et al*. [@bib99])
  AcrIIC2    123         *N. meningitidis* prophage                            Guilt-by-association \[*aca3*\]                                    WP_042743678.1     II-C \[Nme, Hpa, Smu, SauCas9, SpyCas9, FnoCas9, CjeCas9\]   Binds to the bridge helix (BH)-REC1 region (blocks DNA binding)                                                                                 Dimeric structure; each monomer 6-stranded antiparallel β-sheet (half-barrel structure) flanked by 2 α-helices (the C-terminal α-helix is embedded into the half-barrel)     6J9K, 6J9L, 6J9M         (Pawluk *et al*. [@bib66]), (Lee *et al*. [@bib49]), (Zhu *et al*. [@bib99])
  AcrIIC3    116         *N. meningitidis* prophage                            Guilt-by-association \[*aca3*\]                                    WP_042743676.1     II-C \[Nme, Hpa, Smu\]                                       Binds to the HNH domain opposite to the active site, and the REC lobe (hinders DNA binding, blocks DNA cleavage, forces Cas9 dimerization)      4-stranded antiparallel β-sheet + 3 α-helices at either side of the β-sheet                                                                                                  6J9N                     (Pawluk *et al*. [@bib66]), (Lee *et al*. [@bib49]), (Zhu *et al*. [@bib99])
  AcrIIC4    88          *Haemophilus parainfluenzae* prophage                 Guilt-by-association \[*aca* not reported\]                        WP_049372635       II-C \[Nme, Hpa, Smu\]                                       Binds to the Cas9 (blocks DNA binding)                                                                                                          ---                                                                                                                                                                          ---                      (Lee *et al*. [@bib49])
  AcrIIC5    130         *Simonsiella muelleri* transfer element               Guilt-by-association \[*aca* not reported\]                        WP_002642161.1     II-C \[Nme, Hpa, Smu\]                                       Binds to the Cas9 (blocks DNA binding)                                                                                                          ---                                                                                                                                                                          ---                      (Lee *et al*. [@bib49])
  AcrVA1     170         *Moraxella bovoculi* prophage                         Self-targeting, Guilt-by-association \[*acrIF11*\]                 WP_046701302.1     V-A \[Mbo, Asp, Lba, Fno\]                                   ---                                                                                                                                             ---                                                                                                                                                                          ---                      (Marino *et al*. [@bib54]), (Watters *et al*. [@bib2_82_1558689739780])
  AcrVA2     322         *M. bovoculi* prophage                                Self-targeting, Guilt-by-association \[*acrIF11*\]                 AKG19228.1         V-A \[Mbo\]                                                  ---                                                                                                                                             ---                                                                                                                                                                          ---                      (Marino *et al*. [@bib54])
  AcrVA3     168         *M. bovoculi* prophage                                Self-targeting, Guilt-by-association \[*acrIF11*\]                 AKG19230.1         V-A \[Mbo\], I-C \[Mbo\]                                     ---                                                                                                                                             ---                                                                                                                                                                          ---                      (Marino *et al*. [@bib54])
  AcrVA4     234         *M. bovoculi* prophage                                Self-targeting                                                     WP_046699156.1     V-A \[Mbo, Lba\]                                             ---                                                                                                                                             ---                                                                                                                                                                          ---                      (Watters *et al*. [@bib2_82_1558689739780])
  AcrVA5     92          *M. bovoculi* prophage                                Self-targeting                                                     WP_046699157.1     V-A \[Mbo, Lba\]                                             ---                                                                                                                                             ---                                                                                                                                                                          ---                      (Watters *et al*. [@bib2_82_1558689739780])
  Csx27      201         *Bergeyella zoohelcum*                                Guilt-by-association \[*cas13b*\]                                  WP_034985946.1     VI-B                                                         ---                                                                                                                                             ---                                                                                                                                                                          ---                      (Smargon *et al*. [@bib78])

Here, we explore the biological relevance and detail the recent insights into the molecular mechanisms and structures of anti-CRISPR proteins. We also address the development of anti-CRISPRs as 'off-switches' for genome editing and discuss the impact of their use in other biotechnological applications.

BIOLOGICAL RELEVANCE OF ANTI-CRISPR PROTEINS {#sec2}
============================================

The emergence of widespread, specialized and highly diverse phage-encoded proteins that thwart CRISPR-Cas immunity, suggests that Acr proteins play an important role in phage biology. The first identified Acr proteins were shown to inactivate the type I-F CRISPR-Cas system of *P. aeruginosa*, halting the host CRISPR machinery upon phage infection (Bondy-Denomy *et al*. [@bib4]). However, finding other Acr proteins by homology searches proved to be a challenging task due to their low sequence similarity. Instead, it was noted that the genomic neighbourhood of *acr* genes had interesting similarities that could be exploited to discover new Acrs. Typically, many *acr* genes co-occur with a group of genes that were collectively called 'anti-CRISPR-associated genes' (*aca*'s) (Pawluk *et al*. [@bib65]). To date, seven *aca* genes have been identified (Table [3](#tbl3){ref-type="table"}). While the function of *aca*'s is not yet understood, these genes often encode for a protein containing a helix-turn-helix (HTH) motif, suggesting they fulfil a regulatory function (Pawluk *et al*. [@bib65]). Nevertheless, the presence of *aca*'s has been instrumental in finding new Acr proteins and vice-versa, a method that is now known as 'guilt-by-association' (Fig. [1A](#fig1){ref-type="fig"}). In addition, the occurrence of a so-called 'self-targeting' spacer (i.e. a spacer that targets the host\'s own genome) within the CRISPR array is often indicative of a suppressed CRISPR-Cas system due to the presence of a (prophage encoded) *acr* gene (Rauch *et al*. [@bib69]) (Fig. [1B](#fig1){ref-type="fig"}). Furthermore, novel Acr proteins can be found using (high-throughput) screening and testing assays, including transformation of metagenomic libraries in an Acr-selection strain (Fig. [1C](#fig1){ref-type="fig"}) either combined or not with synthetic genetic circuit-based selection for CRISPR-Cas suppression activity (Uribe *et al*. [@bib85]).

###### 

Anti-CRISPR-associated (*aca*) genes used in the guilt-by-association approach.

  Name     Size (aa)   Accession number   References
  -------- ----------- ------------------ ---------------------------------
  *aca1*   79          YP_007392343       (Bondy-Denomy *et al*. [@bib4])
  *aca2*   125         WP_019933869.1     (Pawluk *et al*. [@bib65])
  *aca3*   70          WP_049360086.1     (Pawluk *et al*. [@bib65])
  *aca4*   67          ABR13385.1         (Marino *et al*. [@bib54])
  *aca5*   60          WP_039494319.1     (Marino *et al*. [@bib54])
  *aca6*   65          WP_035450933.1     (Marino *et al*. [@bib54])
  *aca7*   68          WP_064702654.1     (Marino *et al*. [@bib54])

The high diversity of the Acr proteins, their ability to inhibit different (sub)types of CRISPR-Cas systems (I-C, I-D, I-E, I-F, II-A, II-C, V-A, VI-B) (Smargon *et al*. [@bib78]; He *et al*. [@bib34]; Marino *et al*. [@bib54]), their widespread presence and their usual coexistence in the same locus, demonstrate the strong evolutionary pressure that CRISPR-Cas systems exert in Acr arsenal diversification, and vice versa, meeting the Red Queen Hypothesis on the continuous shaping of the host-invader dynamics (Westra *et al*. [@bib93]; van Houte *et al*. [@bib87]).

The origin of Acr proteins remains to be understood, but it is hypothesized that these proteins do not share a common ancestor due to their low structural similarity (Pawluk *et al*. [@bib65]). While it is theorized they represent a product of *de novo* evolution from intergenic regions (Tautz, [@bib84]; Stanley and Maxwell [@bib80]), parallel studies show that they might have derived from other bacterial or viral proteins, as specific nuclease inhibitors, regulatory or even phage capsid proteins (Stanley and Maxwell [@bib80]; Stone *et al*. [@bib81]). Due to their function, *acr* genes were classified as accessory, or 'morons', since they are not strictly necessary in a phage lifecycle (Juhala *et al*. [@bib40]; Brussow, Canchaya and Hardt [@bib9]; Borges, Davidson and Bondy-Denomy [@bib6]). However, when facing specific CRISPR-active hosts, the presence of these genes was shown to increase the fitness of Acr-positive phage populations (Bondy-Denomy *et al*. [@bib4]; Pawluk *et al*. [@bib65]). While previous studies show the activity of CRISPR-Cas systems *in vivo* can clear a targeted phage in as little as 2 min (Garneau *et al*. [@bib26]; Borges *et al*. [@bib7]), the presence of Acr proteins seems to decrease or completely abolish bacterial immunity, classifying it as a major CRISPR-counteracting mechanism for successful phage infection and replication. However, the fast-acting nature of CRISPR-Cas limits the potential of a single phage to overcome the host\'s defence by Acr activity. Recently, it was shown that even though CRISPR-Cas systems are partially affected by the expression of Acr proteins, the latter are not able to confer full protection to their phage associated genome upon a single infection (Borges *et al*. [@bib7]; Landsberger *et al*. [@bib48]) Instead, a critical Acr concentration inside each single cell is necessary for successful host immunosuppression, allowing posterior lytic re-infection or genomic integration of temperate phages (Borges *et al*. [@bib7]; Landsberger *et al*. [@bib48]). It was then demonstrated that a single clonal phage population could inactivate CRISPR-Cas immunity through phage cooperation, where failed infections from 'sacrificial Acr donors' allow accumulation of Acr inhibitors inside a cell, which, upon a certain threshold, leads the 'acceptor' phages to successfully infect and amplify (Borges *et al*. [@bib7]; Landsberger *et al*. [@bib48]). The quantitative demand of Acr proteins for full host immunosuppression postulated that phage concentration has a key role on CRISPR evasion, which is inversely proportional to the strength of each Acr protein (Borges *et al*. [@bib7]; Landsberger *et al*. [@bib48]).

The existence of Acr proteins might also explain the incomplete, absent or deficient CRISPR-Cas systems found in bacteria (Stanley and Maxwell [@bib80]). Prophage integration into the host chromosome and consistent Acr expression might result in CRISPR-Cas inactivating mutations, loss of *cas* genes and even complete loss of CRISPR-Cas systems (Stanley and Maxwell [@bib80]). Interestingly, although it is evident that Acr proteins are relevant for the phage it originated from, bacteria might also benefit from the stable expression of these proteins (e.g. from prophage regions). For example, inhibition of CRISPR-Cas immunity might enhance HGT in these hosts, which can have a positive contribution to bacterial fitness upon acquisition of beneficial foreign genetic material (Bondy-Denomy *et al*. [@bib4]; Jiang *et al*. [@bib39]; Pawluk *et al*. [@bib63]; Borges *et al*. [@bib7]; Stanley and Maxwell [@bib80]).

MECHANISMS AND STRUCTURES OF ANTI-CRISPR PROTEINS {#sec3}
=================================================

Over the last six years, a series of studies interlacing genetic, biochemical and structural analyses have elucidated the mechanism of action of 12 Acr proteins from different families. Although many Acrs remain to be tested for anti-adaptation activity, the vast majority of the currently characterized Acr proteins act at the interference phase by directly blocking target DNA binding or cleavage (Fig. [2](#fig2){ref-type="fig"}). These two general modes-of-action are spread among both class 1 and class 2 Acr proteins, with distinct molecular mechanisms (Borges, Davidson and Bondy-Denomy [@bib6]).

![Schematic overview of the different Acrs and their mechanisms. The green boxes on the left show the different stages of CRISPR-Cas immunity. The columns indicate which CRISPR-Cas type is suppressed by which (group of) Acrs. Acrs are depicted as circles with their abbreviated names (e.g. AcrIF3 is abbreviated to IF3). A dashed line indicates a suggested role for the particular Acr or that the Acr mechanism remains to be elucidated. Note that most Acrs appear to suppress the interference stage, whereas only one Acr (AcrIF3) suppressed different stages.](fnz098fig2){#fig2}

Class 1 Anti-CRISPR Proteins {#sec3-1}
----------------------------

The class 1 Acr proteins studied up till now all impede type I (subtype C, D, E or F) CRISPR-Cas systems (Table [1](#tbl1){ref-type="table"}). Two mechanistic routes have been described for Acrs to perturb CRISPR interference: the most common is the direct interaction with the Cascade surveillance complex to prevent DNA binding (Bondy-Denomy *et al*. [@bib5]; van Erp *et al*. [@bib86]; Maxwell *et al*. [@bib56]; Chowdhury *et al*. [@bib14]; Guo *et al*. [@bib29]; Peng *et al*. [@bib67]), while the less common involves the direct interaction with the effector nuclease Cas3, which typically gets recruited upon successful target binding by the Cascade, to block DNA cleavage (Pawluk *et al*. [@bib63]; Bondy-Denomy *et al*. [@bib5]; Pawluk *et al*. [@bib65]; Wang *et al*. [@bib90]; Wang *et al*. [@bib91]; Pawluk *et al*. [@bib64]).

A) Preventing DNA Binding via Interaction with the Cascade Complex {#sec3-2}
------------------------------------------------------------------

### Steric occlusion of DNA binding {#sec3-2-1}

AcrIF1 from *P. aeruginosa* phage JBD30 binds along the hexameric Cas7f spine with a stoichiometry of 2--3 molecules per Cascade complex (Bondy-Denomy *et al*. [@bib5]). Several high-resolution cryo--electron microscopy and nuclear magnetic resonance (NMR) studies combined with site-directed mutagenesis indicated that AcrIF1 molecules bind tightly at different positions of the *P. aeruginosa* Cascade complex. More specifically, two AcrIF1 monomers sit on the Cas7f.4 and Cas7f.6 thumbs (Tyr6, Tyr20 and Glu31 lying on a single interaction surface of each monomer interact with the conserved Lsy85 on the Cas7f thumb), resulting in a conformational change that sterically blocks access of the crRNA guide to the target DNA, while a possible third monomer binds to a Cas7 region in close proximity to the Cas8f-Cas5f tail, which is crucial for target DNA binding (Bondy-Denomy *et al*. [@bib5]; Maxwell *et al*. [@bib56]; Chowdhury *et al*. [@bib14]; Guo *et al*. [@bib29]; Peng *et al*. [@bib67]; Gabrieli *et al*. [@bib24]).

### DNA mimicry {#sec3-2-2}

While AcrIF1 exploits three different binding modes to disrupt target DNA recognition by the Cascade complex, AcrIF2 from *P. aeruginosa* phage D3112 mediates inhibition by interacting with a single site within the complex. AcrIF2 directly competes with the target DNA for a positively charged binding interface on the Cas5f:Cas8f tail between the Cas7f.6 thumb and the Cas8f hook, a region called the 'lysine-rich vise' (Bondy-Denomy *et al*. [@bib5]). The small acidic AcrIF2 protein behaves as a DNA mimic, as the numerous acidic residues on its surface adopt a pseudo-helical distribution, resembling a double-stranded DNA (dsDNA) molecule. The interaction sites of AcrIF2 and DNA on the Cas5f:Cas8f heterodimer overlap partially, and AcrIF2 binding shoves the Cas8f hook away from the DNA-association pocket, sterically hampering the access of the dsDNA to the Cascade complex. Additional interactions of AcrIF2 with basic residues crucial for DNA binding further ensure obstruction of target DNA binding (van Erp *et al*. [@bib86]; Chowdhury *et al*. [@bib14]; Guo *et al. et al*. [@bib29]; Peng *et al*. [@bib67]). Given the close proximity of the interaction sites of AcrIF2 and the third AcrIF1 monomer, when cooperating, AcrIF1 exhibits a maximum of two binding modes while AcrIF2 activity remains intact (Peng *et al*. [@bib67]).

Similar to AcrIF2, AcrIF10 from *Shewanella xiamenensis* prophage also mimics DNA by occupying a region on the Cas5f:Cas8f heterodimer that closely overlaps with the binding site of AcrIF2 (possibly Cas8f K71 and R78, Cas5f R90 and Cas7f K299). However, instead of wrenching the Cas8f hook away, AcrIF10 triggers a partially closed state of the hook swinging it toward Cas7.6f (similar but smaller than the movement caused by DNA binding), displaying the conformational flexibility of this domain and implying the need of additional interactions for absolute closure of the hook. Intriguingly, AcrIF10 and dsDNA display different charge profiles on the interaction surface; nevertheless, they interact with closely overlapping regions in the Cascade complex to prevent DNA binding (Guo *et al*. [@bib29]).

The first archaeal Acr protein identified, AcrID1, was shown to directly interact as a homodimer with two copies of the large subunit (Cas10d) of the type I-D Cascade complex in *Sulfolobus islandicus*. The strong negatively charged surface of this protein suggests that it may behave as a DNA mimic, such as AcrIF2. In addition, conserved residues on the surface of AcrID1, such as Glu21, Lys34, Tyr55, Glu81, Arg92 and Trp91, may have a key role in inter-protein interactions. However, the exact mechanism of AcrID1 still remains to be explored (He *et al*. [@bib34]).

### Unknown mechanisms {#sec3-2-3}

AcrIE3 and AcrIF4 from *P. aeruginosa* phage DMS3 and JBD26, respectively, have been shown to associate with the Cascade complex to hinder DNA binding, though via an unknown mechanism (Pawluk *et al*. [@bib63]; Bondy-Denomy *et al*. [@bib5]).

B) Preventing DNA Cleavage via Interaction with the Cas3 Nuclease {#sec3-3}
-----------------------------------------------------------------

### Disruption of binding to the Cascade:dsDNA chimera {#sec3-3-1}

Cryo-electron microscopy and X-ray crystallography demonstrated that the AcrIF3 protein from *P. aeruginosa* phage JBD5 forms a homodimer that binds to the Cas3 nuclease (Wang *et al*. [@bib90]; Wang *et al*. [@bib91]). High binding affinity was observed, since more than half of the AcrIF3 surface interacts with the Cas3 protein, forming several hydrogen bonds and hydrophobic interactions. As a consequence, the interaction sites for both the non-complementary DNA strand and the Cascade complex are blocked. Specifically, one AcrIF3 monomer occupies the helicase domain (HD) and the Linker region of Cas3, while the other monomer relates to the C-terminal domain (CTD) (Tyr97, Trp93, and a large network of hydrogen bonds), which altogether constitute the internal cleft of the Cas3 structure. By covering this cleft, AcrIF3 disrupts association with the target DNA (non-complementary strand) and locks the ATP-dependent Cas3 nuclease in an inactive ADP-bound form (Wang *et al*. [@bib90]; Wang *et al*. [@bib91]). Noteworthy, the Cas3 effector nuclease/helicase is fused to the Cas2 protein in type I-F systems and thereby forms an integral part of the type I-F (primed) adaptation machinery, hinting at the functional link between adaptation and interference, as shown recently (Kunne *et al*. [@bib47]; Staals *et al*. [@bib79]; Fagerlund *et al*. [@bib22]). Interestingly, AcrIF3 dimer binds to the opposite site of Cas2, thus not influencing the assembly of the Cas1-Cas2-Cas3 complex (Rollins *et al*. [@bib71]). However, the dimer obstructs the recruitment of the Cascade:dsDNA chimera to Cas3, preventing the generation of precursor protospacer DNA. Consequently, AcrIF3 blocks both primed spacer acquisition and crRNA interference (Vorontsova *et al*. [@bib89]; Wang *et al*. [@bib91]).

### Unknown mechanisms {#sec3-3-2}

Akin to AcrIF3, AcrIE1 from *P. aeruginosa* phage JBD5 directly associates with the ATP-dependent Cas3 nuclease, without affecting the binding ability of the Cascade to the target DNA. Due to the structural homology between Cas3 proteins of type I-F and I-E CRISPR-Cas systems, it is likely that AcrIF3 and AcrIE1 either adopt distinct modes of binding to the same surface or target unrelated regions on the Cas3 protein, hindering target DNA cleavage (Pawluk *et al*. [@bib63]; Pawluk *et al*. [@bib64]).

Class 2 anti-CRISPR proteins {#h2content1558351704561}
----------------------------

Class 2 Acr proteins have been discovered for type II (subtype A and C), type V (subtype A) and type VI (subtype B) CRISPR-Cas systems (Table   [2](#tbl2){ref-type="table"}). Almost all type II Acrs characterized to date directly interact with the Cas9 endonuclease, although by distinct mechanisms, as described below.

A) Preventing DNA Binding via Interaction with the Cas9 Protein {#sec3-4}
---------------------------------------------------------------

### DNA mimicry and steric occlusion of DNA binding and cleavage {#sec3-4-1}

Both AcrIIA2 and AcrIIA4 from *Listeria monocytogenes* prophage J0161a/b have been demonstrated *in vivo* and *in vitro* to directly interact with single-guide RNA (sgRNA)-loaded SpyCas9, abolishing DNA binding and cleavage (Dong *et al*. [@bib18]; Rauch *et al*. [@bib69]; Yang and Patel [@bib96]; Basgall *et al*. [@bib2]). Biochemical and structural studies have indicated that AcrIIA4 binds to several regions within SpyCas9. First, AcrIIA4 (Asp14, Asp37, Glu40, Asp69 and Glu70) associates with the PAM-interacting domain (Glu1108, Ser1109, Ser1216, Lys1200, Arg1335 and Arg1333) through an acidic surface that mimics a negatively-charged dsDNA molecule, thereby hampering the initial PAM searching stage. Second, AcrIIA4 (Asp14 and Asn36) interacts with the Topo-homology domain (Glu1108, Ser1109 and Ser1136), also known as DNA-melting region, putatively preventing DNA binding or unwinding. Third, AcrIIA4 (Leu19--Gln29) forms numerous surface complementarities with the concave surface of SpyCas9 at the RuvC domain (Asn767, Thr13, Ala764 and Arg976), abrogating the endonuclease activity. In addition, AcrIIA4 binds the linker between RuvC and HNH domains, sterically blocking conformational changes necessary for DNA cleavage (Dong *et al*. [@bib18]; Shin *et al*. [@bib76]; Yang and Patel, [@bib96]). Similar to AcrIIA4, AcrIIA2 prevents target DNA recognition, binding and cleavage. Specifically, AcrIIA2 (Asp71 and Glu72) associates with the PAM-interacting domain (Arg1335 and Arg1333), the WED domain (Lys1107, Glu1108, Ser1109 and Ser1136 of WED domain interact with His37, Asp38, Glu93 and Asp96 of AcrIIA2), the HNH domain (Gln774 and Arg778 interact with Asn19 of AcrIIA2) and the REC2 domain (Lys268 and Asp269 interact with Gln7, Thr28 and Asp30 of AcrIIA2) (Jiang *et al*. [@bib38]; Liu *et al*. [@bib50]). Notably, both AcrIIA4 and AcrIIA2 are not able to bind to SpyCas9 in the absence of a preloaded sgRNA, as sgRNA-binding is required for the formation of the Acr-interaction surface of SpyCas9 (Dong *et al*. [@bib18]; Shin *et al*. [@bib76]; Yang and Patel [@bib96]; Jiang *et al*. [@bib38]; Liu *et al*. [@bib50]).

### DNA and sgRNA mimicry {#sec3-4-2}

Although AcrIIC2 from *Neisseria meningitidis* prophage was previously speculated to associate with catalytic residues of the NmeCas9 HNH domain (Pawluk *et al*. [@bib66]; Harrington *et al*. [@bib32]), a recent biochemical and structural study revealed interaction with the NmeCas9 bridge helix (BH)-REC1 domain (residues 51--241) (Zhu *et al*. [@bib99]). Indeed, AcrIIC2 forms an homodimer, forming an acidic groove on top of the dimer. The residues in this groove (E18, N23/D24/E25 and residues 109--124) strongly bind to the arginine-rich α helix of BH (residues 56--79; mainly R62, R63, R70 and R73). As such, the AcrIIC2 dimer significantly impedes sgRNA loading to apoNmeCas9, and abrogates dsDNA binding to the sgRNA-NmeCas9-AcrIIC2 complex. Remarkably, AcrIIC2 requires the apo form for effective inhibition, being the first Acr reported to directly interfere with the sgRNA loading to Cas9 (Zhu *et al*. [@bib99]).

### Dimerization of Cas9 {#sec3-4-3}

AcrIIC3 from *N. meningitidis* prophage hinders DNA binding and induces NmeCas9 dimerization by associating with the HNH domain and the REC lobe, respectively (Zhu *et al*. [@bib99]). AcrIIC3 (K532-Y540, R557-H563) interacts with a non-conserved region of the NmeCas9 HNH domain opposite to the active site (L58, N60, R33, V34 and D38 among others) (Zhu *et al*. [@bib99]), allowing PAM detection but hampering complete R-loop formation (Harrington *et al*. [@bib32]). Hence, the binding affinity for target DNA is decreased, while DNA cleavage is abrogated. AcrIIC3 additionally associates with the REC lobe, triggering NmeCas9 dimerization with a 2:2 stoichiometry. Each AcrIIC3 molecule binds to the HNH domain as well as the REC lobe of the same or another NmeCas9 molecule, forcing AcrIIC3-Cas9 dimerization and preventing target DNA loading (Zhu *et al*. [@bib99]).

### Unknown mechanisms {#sec3-4-4}

Recently, AcrIIC4 and AcrIIC5 were discovered in a *Haemophilus parainfluenzae* prophage and a *Simonsiella muelleri* transfer element. Both were shown to impede the Cas9:sgRNA complex from binding to the target DNA, following an unknown mode-of-action (Lee *et al*. [@bib49]).

B) Preventing DNA Cleavage via Interaction with the Cas9 Protein at the Catalytic Site {#sec3-5}
--------------------------------------------------------------------------------------

Like the type I AcrIF3, AcrIIC1 from *N. meningitidis* MGE allows binding of the CRISPR interference complex to the target DNA, though hampering DNA cleavage. Biochemical and structural characterization have revealed that AcrIIC1 specifically binds to the active site of the NmeCas9 HNH domain (D587, H588), blocking cleavage of the target strand and preventing conformational changes necessary for the activation of the RuvC domain, which would theoretically catalyse cleavage of the non-target strand. Thus, the sgRNA-loaded Cas9 remains bound to the target DNA, being trapped in a catalytically inactive state. To achieve high stability of the inter-protein interaction, AcrIIC1 additionally associates with five neighbouring residues of the HNH domain (K549, K551, D598, K603, N616). Similar to AcrIIC1, AcrIIC2 associates with catalytic residues of the NmeCas9 HNH domain, albeit the exact mode-of-action is still elusive (Pawluk *et al*. [@bib66]; Harrington *et al*. [@bib32]).

C) Preventing CRISPR-Cas Immunity via Putative Binding to RNA or DNA Molecules {#sec3-6}
------------------------------------------------------------------------------

Similar to AcrID1, AcrIIA1 from *L. monocytogenes* prophage J0161a forms a homodimer, though with an unusual two helical-domain structure. The N-terminal domain resembles the HTH motif of transcriptional factors, whilst the CTD adopts an architecture of unknown function. It is anticipated that AcrIIA1 recognizes and associates with heterogeneous RNA molecules to abolish CRISPR-Cas immunity. However, no binding to CRISPR RNA (crRNA), trans-activating RNA (tracrRNA) or their duplex has been observed. AcrIIA1 harbours a positively charged surface around the HTH region, resembling nucleic acid binding motifs of many transcriptional factors that are crucial for RNA and dsDNA recognition. Hence, it would be possible that AcrIIA1 binds to the promoter regions of crRNA or tracrRNA to hinder CRISPR-Cas immunity. However, Cas9 expression levels appeared to be unaffected by AcrIIA1 (Ka *et al*. [@bib41]). The unique structure and function of AcrIIA1 reveals a novel mechanism of action yet unknown among Acr proteins, strengthening our understanding about the versatile and sophisticated ways in which these small proteins may hamper CRISPR-Cas systems (Rauch *et al*. [@bib69]; Ka *et al*. [@bib41]).

D) Preventing RNA Binding or Cleavage via Interaction with the Cas13b Protein {#sec3-7}
-----------------------------------------------------------------------------

Although not associated to a phage genome, through the computational pipeline that guided the discovery of subtype VI-B CRISPR-Cas loci, the accessory protein Csx27 was recently found to repress the interference stages of its associated CRISPR-Cas system (Smargon *et al*. [@bib78]). Experimental testing of *Bergeyella zoohelcum* Csx27 (201 aa) has demonstrated an inhibitory effect of the protein when expressed together with different Cas13b proteins, weakening their RNA interference activity. Even though important details on the mechanism of Csx27 remain to be identified, the current findings suggest a broad activity of the protein among type VI-B loci, relating to a possible regulatory mechanism of phage interference (Smargon *et al*. [@bib78]).

APPLICATIONS OF ANTI-CRISPR PROTEINS {#sec4}
====================================

CRISPR-Cas systems have recently been scrutinised for their potential in biotechnological applications. Type II CRISPR-Cas9 systems raise special interest among the scientific community, due to their programmability and specific nuclease activity, representing the most promising tool on genome editing and modulation studied to date (Komor, Badran and Liu [@bib43]). The use of catalytically inactive Cas9 ('dead', dCas9) was also previously shown to have powerful biotechnological applications. These include CRISPR interference and activation (CRISPRi and CRISPRa), modification of epigenetic marks and gene expression modulation when fused dCas9 to other metabolic key enzymes (Hilton *et al*. [@bib35]). Other applications encompass dynamic genomic imaging, identification of specific genes or genomic loci, monitoring of gene copy and follow-up of chromatin formation and telomere elongation, when combining site-specific sgRNA molecules with fluorescent tagging of dCas9 (EGFT-dCas9) (Rauch *et al*. [@bib69]; Liu *et al*. [@bib51]). Recently, a Cas9-Assisted Targeting of Chromosome segments (CATCH) was also used for nanopore sequencing of a breast cancer gene (Gabrieli *et al*. [@bib24]). Taken together, the quick emergence of CRISPR-based technologies and the continuous quest for finding new CRISPR-Cas nucleases and variants hereof indicates that more (advanced) applications are expected to be developed in the near future. However, full specificity is crucial in these applications, especially those with therapeutic purposes, as off-target events are still one of the main bottlenecks that limit the efficiency of this technology (Zhang *et al*. [@bib98]).

Deeper insight in Acr inhibitory mechanisms might soon allow for precise temporal, spatial and conditional control of CRISPR-Cas systems through an 'on-off switch' regulation. Several AcrIIA and AcrIIC proteins were found to work as 'off-switches' of Cas9 activity in human cell lines (Pawluk *et al*. [@bib66], Rauch *et al*. [@bib69]). The potential of combining these natural CRISPR inhibitors with Cas9 editing systems, tuning its activity in cellular environments, could result in full optimisation of gene editing processes, substantially decreasing off-target events by allowing Acr proteins to accumulate whenever or wherever editing activity is unwanted (Pawluk *et al*. [@bib66]; Rauch *et al*. [@bib69]; Shin *et al*. [@bib76]; Hynes *et al*. [@bib36]). Innovation in the use of Acrs to control CRISPR-Cas editing are expected to quickly emerge, as demonstrated by the combination of an AcrIIA4 hybrid with a LOV2 photosensor for the light-mediated control of genome and epigenome editing by CRISPR-Cas9 effectors in human cells (Bubeck *et al*. [@bib11]). Acr-mediated inhibition was also proven to be effective towards the activity of dCas9 processes (Rauch *et al*. [@bib69]; Liu *et al*. [@bib51]; Nakamura *et al*. [@bib59]) as well as the control of genomic circuits and gene editing with Cas9 (Nakamura *et al*. [@bib59]), once again representing a promising tool for optimization of the activity of these CRISPR-based technologies and future therapeutic and biotechnological applications.

Although no research was performed yet on the possible applications of Csx27, this represents the only protein known to date to repress Cas13b, a type VI CRISPR associated protein. In contrast to most other CRISPR-Cas systems currently classified, prokaryotes carrying type VI CRISPR loci are able to target foreign RNA molecules (Smargon *et al*. [@bib78]). The discovery and employment of Acr proteins able to inhibit these systems might allow modulation of future RNA-based biotechnology applications.

Acr proteins might also benefit gene drive technology. Gene drives are powerful tools to eradicate vector-borne diseases, eliminate pests (e.g. agricultural pests and invasive species) and even increase animal welfare. The technology enables the rapid dissemination of genetic mutation(s) through a population by surpassing Mendelian inheritance rules regardless of the fitness-affecting properties of the introduced mutation (Burt [@bib12]). This is accomplished by turning heterozygous organisms into homozygotes through the incorporation of the desired mutated gene flanked by a homing endonuclease (such as CRISPR-Cas) and a corresponding guide RNA (targeting the wild-type gene) in the genome. Upon recognition of the target sequence (i.e. the wild-type gene) on the homologous chromosome, the homing endonuclease will introduce a break at the target site. If this event is followed by homologous recombination, a cassette consisting of the mutated gene flanked by the homing nuclease and the guide RNA will replace the wild-type locus. However, one of the main technological hurdles to overcome is the current inability to effectively control the spreading of a gene drive once out in the environment (DiCarlo *et al*. [@bib17]; Webber, Raghu and Edwards [@bib92]). Acrs can be used as a molecular tool to control this spread. These proteins have been shown to reduce the efficiency of the homing nuclease in a tweakable manner (Basgall *et al*. [@bib2]; Roggenkamp *et al*. [@bib70]). Acrs are also envisioned to enable timed drive activation and to aid anti-gene drives in destroying the original gene drive construct (immunization) (Basgall *et al*. [@bib2]). The latter can be achieved by introducing an *acr* encoding gene instead of a mutated gene, as part of a gene drive. This gene drive should make use of a homing endonuclease which is not suppressed by the respective *acr* gene. Though gene drive efficiency can be partially controlled via sgRNA design (Noble *et al*. [@bib60]; Roggenkamp *et al*. [@bib70]; Yan and Finnigan [@bib95]), incorporation of Acrs in the molecular design to control spreading is advantageous over regulation via sgRNA design since Acrs work directly against the homing endonuclease whereas sgRNA based molecular principles are case specific.

Finally, Acr proteins might represent a powerful tool to enable phage therapy in CRISPR-active hosts. The emergence of multidrug resistant bacteria represents a rising scientific concern due to the possible implications of antibiotic unresponsive infections. Phage therapy poses an interesting alternative to the control of these bacterial infections (Nobrega *et al*. [@bib61]), and Acr-mediated inhibition of active CRISPR-Cas systems might facilitate the employment of known phages that would be otherwise targeted by the bacterial immune system. The possibility of using studied phages, instead of the constant search and characterisation of new ones not yet targeted by the bacterial CRISPR-Cas system, might represent a therapeutic advantage and lead to faster treatment.

OUTLOOK {#sec5}
=======

A limited number of Acr proteins has been identified so far, but their sequence and structural diversity is already remarkable. The discovery of new Acrs, especially those targeting CRISPR-Cas (sub)types for which Acr proteins have not yet been found, is expected to clarify the number of distinct Acr protein families and how widespread they are. The development of new Acr identification strategies will certainly be required to avoid biases created by current pipelines. Clarification of the mechanisms of multiple Acr proteins, including the characterisation of AcrVA1, AcrVA4 and AcrVA5 (Dong *et al*. [@bib19]; Knott *et al*. [@bib42]) while our study was under review, is expected to fuel the Acr-based fine-tuning of CRISPR-Cas applications, such as gene editing or gene drives.

Because bacteria and phages have co-evolved together for billions of years, it is anticipated that bacteria have developed mechanisms to counteract Acr protein activity. Possible strategies have been hinted, including the accumulation of multiple types of CRISPR-Cas systems in a single cell (e.g. type I-E and I-F systems in *P. aeruginosa*), mutation of *cas* genes (Pausch *et al*. [@bib62]), or silencing of *acr* gene expression. Proper research on the field will certainly increase our understanding on bacterial evolution, and also expand the CRISPR toolbox for biotechnological applications.
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